Lupus (SLE): who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• CD19 80
• BCMA 38
• STING 0
• CD20 9
• SGLT2 3
• STAT3 0
• NLRP3 0
• mTOR 0
• JAK 0
• TNF 0
• IL-17 1
• IL-6 0
• PI3K 0
• CD40 0
• TYK2 0
• CTLA-4 0
• FOXP3 0
• PD-1 0
• PPAR 0
• AMPK 0
• CD38 1
• IL-1 0
• NRF2 0
• TP53 0
• AKT 0
• AQP4 0
• CD22 1
• CXCR4 0
• IL-23 0
• APOL1 0
• BRD4 0
• BTK 0
• CTNNB1 0
• GPX4 0
• HIF-1 0
• HMGB1 0
• IL-15 1
• MAPK 0
• PD-L1 0
• SIRT1 0
• TIGIT 0
• TLR4 0
• ANGPTL3 0
• BCL-2 0
• CD123 0
• COX-2 0
• DPP-4 0
• ERK 0
• EZH2 0
• FGFR 0
• FTO 0
• G6PD 0
• GLP-1 0
• IDO1 0
• IL-4 0
• KRAS 0
• LAG-3 0
• MDM2 0
• METTL3 0
• MYC 0

EU-13 is a filter, not a ranking: it only narrows the list.

6 of 6+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease

  NCT06935474· AbelZeta Inc.· Updated 16 Jul 2026

  “Sponsor decision to discontinue development and pursue an alternative clinical development strategy”Registry text, quoted unchanged. Source

• Terminated

  IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy

  NCT06462144· The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School· Updated 28 Jan 2026

  “The collaborating party has adjusted its R\&D strategy and terminated the study.”Registry text, quoted unchanged. Source

• Withdrawn

  A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

  NCT06153095· Lyell Immunopharma, Inc.· Updated 10 Feb 2025

  “Sponsor decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)

  NCT07371468· GlaxoSmithKline· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 33
• Mendelian Randomization Analysis 41
• CRISPR-Cas Systems 1
• Gene Expression Profiling 101
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 5
• Proteomics 35
• Metabolomics 23
• Mass Spectrometry 5
• Flow Cytometry 35
• Immunohistochemistry 8
• Liquid Biopsy 2
• Positron-Emission Tomography 4
• Magnetic Resonance Imaging 49
• Machine Learning 37
• Deep Learning 3
• Cohort Studies 111
• Genome-Wide Association Study 54

See which targets of this disease your abstract mentions, and go to the people working on them.